Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays

Class-Sparing Regimens for Initial Treatment of HIV-1 Infection

Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074609 · Cited by 680 · see citing works

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., & Lamarre, D. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3763-3769.1996 · Cited by 297 · see citing works

Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine

Kempf, D. J., King, M. S., Bernstein, B. M., Cernohous, P., Bauer, E., Moseley, J. L., Gu, K., Hsu, A., Brun, S., & Sun, E. (2004) · The Journal of Infectious Diseases · doi:10.1086/380509 · Cited by 217 · see citing works

Near Full-Length Clones and Reference Sequences for Subtype C Isolates of HIV Type 1 from Three Different Continents

Rodenburg, C. M., Li, Y., Trask, S. A., Chen, Y., Decker, J. M., Robertson, D. L., Kalish, M. L., Shaw, G. M., Allen, S., Hahn, B. H., et al. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/08892220150217247 · Cited by 181 · see citing works

A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism

Nijhuis, M., van Maarseveen, N. M., Lastère, S., Schipper, P. J., Coakley, E. P. G., Glass, B., Rovenska, M., de Jong, D. C. M., Chappey, C., Goedegebuure, I. W., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040036 · Cited by 168 · see citing works

Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors

Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M. F., Nagashima, K., Gorelick, R. J., Mardy, S., Tang, C., Summers, M. F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108005200 · Cited by 156 · see citing works

Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir

Côté, H. C. F., Brumme, Z. L., & Harrigan, P. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.589-594.2001 · Cited by 131 · see citing works

Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy

Kempf, D. J., Isaacson, J. D., King, M. S., Brun, S. C., Sylte, J., Richards, B., Bernstein, B. M., Rode, R. A., & Sun, E. (2002) · Antiviral Therapy · doi:10.1177/135965350200700305 · Cited by 123 · see citing works

Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease Inhibitors

Bally, F., Martínez, R., Peters, S., Sudre, P., & Telenti, A. (2000) · AIDS Research and Human Retroviruses · doi:10.1089/08892220050116970 · Cited by 123 · see citing works

Evidence of Two Distinct Subsubtypes within the HIV-1 Subtype A Radiation

Gao, F., Vidal, N., Li, Y., Trask, S. A., Chen, Y., Kostrikis, L. G., Ho, D. D., Kim, J., Oh, M., Choe, K., et al. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201750236951 · Cited by 98 · see citing works

Construction and Analysis of an Infectious Human Immunodeficiency Virus Type 1 Subtype C Molecular Clone

Ndung’u, T., Renjifo, B., & Essex, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.4964-4972.2001 · Cited by 87 · see citing works

Gag Non-Cleavage Site Mutations Contribute to Full Recovery of Viral Fitness in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Myint, L., Matsuda, M., Matsuda, Z., Yokomaku, Y., Chiba, T., Okano, A., Yamada, K., & Sugiura, W. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.444-452.2004 · Cited by 85 · see citing works

Gag Determinants of Fitness and Drug Susceptibility in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Parry, C. M., Kohli, A., Boinett, C. J., Towers, G. J., McCormick, A., & Pillay, D. (2009) · Journal of Virology · doi:10.1128/jvi.02356-08 · Cited by 80 · see citing works

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients

Malet, I., Roquebert, B., Dalban, C., Wirden, M., Amellal, B., Agher, R., Simon, A., Katlama, C., Costagliola, D. G., Cálvez, V., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.06.012 · Cited by 58 · see citing works

Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Delaugerre, C., Flandre, P., Chaix, M., Ghosn, J., Raffi, F., Dellamonica, P., Jaeger, H., Shürmann, D., Cohen-Codar, I., Van, P. N., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01643-08 · Cited by 53 · see citing works

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients

Naeger, L. K., & Struble, K. A. (2006) · AIDS · doi:10.1097/01.aids.0000218548.77457.76 · Cited by 46 · see citing works

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097 · see citing works

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works

HIV-1 drug resistance and resistance testing

Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 337 · see citing works

Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70

Kemp, S. A., Meng, B., Ferriera, I. A., Datir, R., Harvey, W. T., Papa, G., Lytras, S., Collier, D. A., Mohamed, A., Gallo, G., et al. (2020) · doi:10.1101/2020.12.14.422555 · Cited by 252 · see citing works

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome

Rosenbloom, D. I. S., Hill, A. L., Rabi, S. A., Siliciano, R. F., & Nowak, M. A. (2012) · Nature Medicine · doi:10.1038/nm.2892 · Cited by 188 · see citing works

Human Immunodeficiency Virus gag and protease: partners in resistance

Fun, A., Wensing, A. M. J., Verheyen, J., & Nijhuis, M. (2012) · Retrovirology · doi:10.1186/1742-4690-9-63 · Cited by 139 · see citing works

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance

Rabi, S. A., Laird, G. M., Durand, C. M., Laskey, S. B., Shan, L., Bailey, J. R., Chioma, S., Moore, R. D., & Siliciano, R. F. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67399 · Cited by 138 · see citing works

Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant

Mlčochová, P., Collier, D. A., Ritchie, A. V., Assennato, S. M., Hosmillo, M. D. T., Goel, N., Meng, B., Chatterjee, K., Mendoza, V., Temperton, N. J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100099 · Cited by 69 · see citing works

The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs

Wainberg, M. A., & BRENNER, B. G. (2012) · Molecular Biology International · doi:10.1155/2012/256982 · Cited by 66 · see citing works

The Impact of HIV-1 Drug Escape on the Global Treatment Landscape

Collier, D. A., Monit, C., & Gupta, R. K. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.06.010 · Cited by 64 · see citing works

Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors

Basson, A. E., Rhee, S., Parry, C. M., El‐Khatib, Z., Charalambous, S., de Oliveira, T., Pillay, D., Hoffmann, C. J., Katzenstein, D. A., Shafer, R. W., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04215-14 · Cited by 55 · see citing works

Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors

Hassam, M., Basson, A. E., Liotta, D. C., Morris, L., van Otterlo, W. A. L., & Pelly, S. C. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3000462 · Cited by 52 · see citing works

Outcome of patients on second line antiretroviral therapy under programmatic condition in India

Chakravarty, J., Sundar, S., Chourasia, A., Singh, P. N., Kurle, S. N., Tripathy, S. P., Chaturbhuj, D. N., Rai, M., Agarwal, A. K., Mishra, R. N., et al. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1270-8 · Cited by 52 · see citing works

Performance Evaluation of the SAMBA II SARS-CoV-2 Test for Point-of-Care Detection of SARS-CoV-2

Assennato, S. M., Ritchie, A. V., Nadala, C., Goel, N., Tie, C., Nadala, L. M., Zhang, H., Datir, R. P., Gupta, R. K., Curran, M. D., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01262-20 · Cited by 42 · see citing works

Application of the Huisgen cycloaddition and ‘click’ reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors

Pribut, N., Veale, C. G. L., Basson, A. E., van Otterlo, W. A. L., & Pelly, S. C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.05.082 · Cited by 40 · see citing works

Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility and Replication Capacity

Parry, C. M., Kolli, M., Myers, R. E., Cane, P. A., Schiffer, C. A., & Pillay, D. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01228-10 · Cited by 39 · see citing works

Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds

Moranguinho, I., Taveira, N., & Bártolo, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065905 · Cited by 37 · see citing works

Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis

Collier, D. A., Iwuji, C. C., Derache, A., de Oliveira, T., Okesola, N., Calmy, A., Dabis, F., Pillay, D., & Gupta, R. K. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix015 · Cited by 37 · see citing works

Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen

Ghosn, J., Delaugerre, C., Flandre, P., Galimand, J., Cohen-Codar, I., Raffi, F., Delfraissy, J., Rouzioux, C., & Chaix, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024798 · Cited by 36 · see citing works

Genotypic resistance testing in routine clinical care

Dunn, D. T., Coughlin, K., & Cane, P. A. (2011) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834732e8 · Cited by 30 · see citing works

Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV ‐1 protease, reverse transcriptase, and integrase inhibitors

Saladini, F., Giannini, A., Boccuto, A., Vicenti, I., & Zazzi, M. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22206 · Cited by 29 · see citing works

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor

Barber, T., Harrison, L., Asboe, D., Williams, I. G., Kirk, S., Gilson, R. J. C., Bansi‐Matharu, L., Pillay, D., & Dunn, D. T. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr569 · Cited by 27 · see citing works

Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Pribut, N., Basson, A. E., van Otterlo, W. A. L., Liotta, D. C., & Pelly, S. C. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00549 · Cited by 27 · see citing works

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial

Sutherland, K. A., Parry, C. M., McCormick, A., Kapaata, A. A., Lyagoba, F., Kaleebu, P., Gilks, C. F., Goodall, R. L., Spyer, M. J., Kityo, C. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137834 · Cited by 26 · see citing works

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK

Bouzidi, K. E., White, E., Mbisa, J. L., Sabin, C. A., Phillips, A. N., Mackie, N., Pozniak, A., Tostevin, A., Pillay, D., & Dunn, D. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw343 · Cited by 26 · see citing works

Novel indole sulfides as potent HIV-1 NNRTIs

Brigg, S. E., Pribut, N., Basson, A. E., Avgenikos, M., Venter, R., Blackie, M., van Otterlo, W. A. L., & Pelly, S. C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.006 · Cited by 25 · see citing works

Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I

Gregson, J., Rhee, S. Y., Datir, R., Pillay, D., Perno, C. F., Derache, A., Shafer, R. S., & Gupta, R. K. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz631 · Cited by 24 · see citing works

Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1

Sutherland, K. A., Mbisa, J. L., Cane, P. A., Pillay, D., & Parry, C. M. (2013) · Journal of General Virology · doi:10.1099/vir.0.055624-0 · Cited by 22 · see citing works

ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties

Pribut, N., D’Erasmo, M. P., Dasari, M., Giesler, K. E., Iskandar, S., Sharma, S. K., Bartsch, P. W., Raghuram, A., Bushnev, A. S., Hwang, S. S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01083 · Cited by 22 · see citing works

Accumulation of P(T/S)AP Late Domain Duplications in HIV Type 1 Subtypes B, C, and F Derived from Individuals Failing ARV Therapy and ARV Drug-Naive Patients

Martins, A. N., Arruda, M. B., Pires, A. F., Tanuri, A., & Brindeiro, R. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0282 · Cited by 21 · see citing works

Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types

Yeo, J. Y., Koh, D. W., Yap, P., Goh, G.-R., & Gan, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010370 · Cited by 20 · see citing works

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir

Sutherland, K. A., Ghosn, J., Gregson, J., Mbisa, J. L., Chaix, M., Cohen-Codar, I., Delfraissy, J., Delaugerre, C., & Gupta, R. K. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku365 · Cited by 20 · see citing works

HIV-1 genetic variation and drug resistance development

Megens, S., & Laethem, K. V. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.844649 · Cited by 19 · see citing works

Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors

Knops, E., Brakier‐Gingras, L., Schülter, E., Pfister, H., Kaiser, R., & Verheyen, J. (2011) · Medical Microbiology and Immunology · doi:10.1007/s00430-011-0224-z · Cited by 18 · see citing works

Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara)

Gilks, C. F., Walker, A. S., Dunn, D. T., Gibb, D. M., Kikaire, B., Reid, A., Musana, H. W., Mambule, I., Kasirye, R. P., Robertson, V., et al. (2012) · Antiviral Therapy · doi:10.3851/imp2253 · Cited by 18 · see citing works

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy

Giandhari, J., Basson, A. E., Sutherland, K. A., Parry, C. M., Cane, P. A., Coovadia, A. H., Kuhn, L., HUNT, G. M., & Morris, L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02682-15 · Cited by 17 · see citing works

The impact of Gag non-cleavage site mutations on HIV-1 viral fitness from integrative modelling and simulations

Samsudin, F., Gan, S. K.-E., & Bond, P. J. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.022 · Cited by 16 · see citing works

Novel indole based NNRTIs with improved potency against wild type and resistant HIV

Müller, R., Mulani, I., Basson, A. E., Pribut, N., Hassam, M., Morris, L., van Otterlo, W. A. L., & Pelly, S. C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.020 · Cited by 15 · see citing works

Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors

Koning, F., Castro, H., Dunn, D. T., Tilston, P., Cane, P. A., Mbisa, J. L., & on behalf of the UK Collaborative Group on HIV Drug Resistance (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt012 · Cited by 15 · see citing works

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa

Sutherland, K. A., Goodall, R. L., McCormick, A., Kapaata, A. A., Lyagoba, F., Kaleebu, P., Thiltgen, G., Gilks, C. F., Spyer, M. J., Kityo, C. M., et al. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0138 · Cited by 15 · see citing works

HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes

Li, G., Verheyen, J., Theys, K., Piampongsant, S., Laethem, K. V., & Vandamme, A. (2014) · Retrovirology · doi:10.1186/preaccept-1386531399130251 · Cited by 14 · see citing works

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes

Sutherland, K. A., Mbisa, J. L., Ghosn, J., Chaix, M., Cohen-Codar, I., Hué, S., Delfraissy, J., Delaugerre, C., & Gupta, R. K. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku296 · Cited by 14 · see citing works

The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains

Mbisa, J. L., Gupta, R. K., Kabamba, D., Mulenga, V., Kalumbi, M., Chintu, C., Parry, C. M., Gibb, D. M., Walker, A. S., Cane, P. A., et al. (2011) · Retrovirology · doi:10.1186/1742-4690-8-31 · Cited by 14 · see citing works

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix

Datir, R. P., Kemp, S. A., Bouzidi, K. E., Mlčochová, P., Goldstein, R. A., Breuer, J., Towers, G. J., Jolly, C. L., Quiñones‐Mateu, M. E., Dakum, P., et al. (2020) · mBio · doi:10.1128/mbio.02036-20 · Cited by 12 · see citing works

Combination antiretroviral therapy and cell–cell spread of wild-type and drug-resistant human immunodeficiency virus-1

Titanji, B. K., Pillay, D., & Jolly, C. L. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000728 · Cited by 13 · see citing works

Expanding the toolbox of metabolically stable lipid prodrug strategies

Toti, K. S., Pribut, N., D’Erasmo, M. P., Dasari, M., Sharma, S. K., Bartsch, P. W., Burton, S. L., Gold, H. B., Bushnev, A. S., Derdeyn, C. A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1083284 · Cited by 12 · see citing works

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors

Manasa, J., Varghese, V., Pond, S. L. K., Rhee, S., Tzou, P. L., Fessel, W. J., Jang, K. S., White, E., Rognvaldsson, T. S., Katzenstein, D. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11893-8 · Cited by 12 · see citing works

Transmission Patterns of HIV-Subtypes A/AE versus B: Inferring Risk-Behavior Trends and Treatment-Efficacy Limitations from Viral Genotypic Data Obtained Prior to and during Antiretroviral Therapy

Avidor, B., Turner, D., Mor, Z., Chalom, S., Riesenberg, K., Shahar, E., Pollack, S., Elbirt, D., Sthoeger, Z. M., Maayan, S. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057789 · Cited by 11 · see citing works

Signatures of omicron-like adaptation in early SARS-CoV-2 variants and chronic infection

Cheng, M. T. K., Altaf, M., Jesu Castin, E., Reuschl, A., Sievers, B. L., Kamelian, K., Mesner, D., Morse, R. B., Abdullahi, A., Meng, B., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116135 · Cited by 9 · see citing works

Comparable Long-Term Efficacy of Lopinavir/Ritonavir and Similar Drug-Resistance Profiles in Different HIV-1 Subtypes

Grossman, Z., Schapiro, J., Levy, I., Elbirt, D., Chowers, M., Riesenberg, K., Olstein-Pops, K., Shahar, E., Istomin, V., Asher, I., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086239 · Cited by 10 · see citing works

Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency

Sutherland, K. A., Collier, D. A., Claiborne, D. T., Prince, J. L., Deymier, M. J., Goldstein, R. A., Hunter, E., & Gupta, R. K. (2016) · Scientific Reports · doi:10.1038/srep38153 · Cited by 9 · see citing works

Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates

Puertas, M. C., Buzón, M. J., Ballestero-Téllez, M., den Eede, P. V., Clotet, B., Prado, J. G., & Martínez‐Picado, J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01636-12 · Cited by 8 · see citing works

Advances in the Synthesis of Diarylpyrimidine as Potent Non-nucleoside Reverse Transcriptase Inhibitors: Biological Activities, Molecular Docking Studies and Structure-activity Relationship: A Critical Review

Suleiman, M., Hasan, A. H., Murugesan, S., Amran, S. I., & Jamalis, J. (2023) · Current Organic Chemistry · doi:10.2174/1385272827666230711173329 · Cited by 7 · see citing works

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir

Byun, H., Papathanasopoulos, M. A., Steegen, K., & Basson, A. E. (2024) · Viruses · doi:10.3390/v16121888 · Cited by 5 · see citing works

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine

Reddy, N., Papathanasopoulos, M. A., Steegen, K., & Basson, A. E. (2024) · Viruses · doi:10.3390/v16091493 · Cited by 4 · see citing works

Building Metabolically Stable and Potent Anti-HIV Thioether-Lipid Analogues of Tenofovir Exalidex: A thorough Pharmacological Analysis

D’Erasmo, M. P., Sharma, S. K., Pribut, N., Basson, A. E., Dasari, M., Bartsch, P. W., Iskandar, S. E., Giesler, K. E., Burton, S. L., Derdeyn, C. A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01510 · Cited by 4 · see citing works

Drug Susceptibility and Replication Capacity of a Rare HIV-1 Subtype C Protease Hinge Region Variant

Zondagh, J., Basson, A. E., Achilonu, I., Morris, L., Dirr, H. W., & Sayed, Y. (2018) · Antiviral Therapy · doi:10.3851/imp3308 · Cited by 4 · see citing works

Spontaneous Mutations in HIV-1 Gag, protease, RT p66 in the first replication cycle and how they appear: Insights from an in vitro BSL2 assay on mutation rates and typesPreprint

Yeo, J. Y., Koh, D. W.-S., Yap, P., Goh, G.-R., & Gan, S. K.-E. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/679852 · Cited by 4 · see citing works

A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors

Ghimire, D., Yuvraj, K. C., Timilsina, U., Goel, K., Nitz, T. J., Wild, C. T., & Gaur, R. (2021) · Retrovirology · doi:10.1186/s12977-021-00553-5 · Cited by 3 · see citing works

Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease

Marie, V., & Gordon, M. L. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1950569 · Cited by 3 · see citing works

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness

Martin, S. A., Cane, P. A., Pillay, D., & Mbisa, J. L. (2021) · Pathogens · doi:10.3390/pathogens10091070 · Cited by 3 · see citing works

Short Communication: High Natural Polymorphism in the gag Gene Cleavage Sites of non-B HIV Type 1 Isolates from Gabon

Liégeois, F., Reteno, D. G. I., Mouinga‐Ondémé, A., Sica, J., & Rouet, F. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0024 · Cited by 2 · see citing works

Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria

Datir, R. P., Bouzidi, K. E., Dakum, P., Ndembi, N., & Gupta, R. K. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz005 · Cited by 2 · see citing works

Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230

Vardhanabhuti, S., Katzenstein, D., Bartlett, J. A., Kumarasamy, N., & Wallis, C. L. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw154 · Cited by 1 · see citing works

Predictive value of gene mutations as a diagnostic tool for ART resistance in a Zambian population

Phiri, T. M. (2012) · SUNScholar (Stellenbosch University)

Determinants of the Development and Evolution of HIV-1 Drug Resistance

Fun, A. (2012) · Utrecht University Repository (Utrecht University)

Role of Phenotypic Investigation in the Era of Routine Genotypic HIV-1 Drug Resistance Testing

Saladini, F., & Vicenti, I. (2016) · Future Virology · doi:10.2217/fvl-2016-0080

Mechanisms of drug resistance development in subtype B and C variants of human immunodeficiency virus type-1

Coutsinos, D. (2011) · doi:10.82308/607

Liquid Chromatography-Mass Spectrometry Metabolomic Analysis of Terminalia ferdinandiana Exell. Fruit Extracts That Inhibit HIV-1 Cell Infection, HIV-1 Reverse Transcriptase and HIV-1 Protease

Cock, I. E., Matthews, B., & Basson, A. E. (2025) · Molecules · doi:10.3390/molecules30081701

SARS-CoV-2 intra-host recombination promotes epistatic spike interactions and temperature-dependent adaptation

Altaf, M., Cheng, M. T. K., González-Vázquez, L. D., Jesu Castin, E., Kemp, S. A., Hisner, R., Martin, D. P., Thukral, L., Meng, B., & Gupta, R. K. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117460

BindingDB Entry 50007358: Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

BindingDB (2021) · UC San Diego · doi:10.7270/q2cj8hs3

BindingDB Entry 50015512: ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.

BindingDB (2023) · UC San Diego · doi:10.7270/q2765k7x

The design and synthesis of novel HIV-1 non-nucleoside reverse transcriptase inhibitors

Pribut, N. (2015) · SUNScholar (Stellenbosch University)

Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1

Sutherland, K. A., Mbisa, J. L., Cane, P. A., Pillay, D., & Parry, C. M. (2013) · Journal of General Virology · doi:10.1099/vir.0.055624-0 · Cited by 22 · see citing works

Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of HIV-1

Sutherland, K. A. (2014) · UCL Discovery (University College London)

Investigating the role of Gag in protease inhibitor susceptibility amongst West African HIV-1 subtypes

Datir, R. P. (2020) · UCL Discovery (University College London) · Cited by 1 · see citing works

Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency

Sutherland, K. A., Collier, D. A., Claiborne, D. T., Prince, J. L., Deymier, M. J., Goldstein, R. A., Hunter, E., & Gupta, R. K. (2016) · Scientific Reports · doi:10.1038/srep38153 · Cited by 9 · see citing works

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy

Giandhari, J., Basson, A. E., Sutherland, K. A., Parry, C. M., Cane, P. A., Coovadia, A. H., Kuhn, L., HUNT, G. M., & Morris, L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02682-15 · Cited by 17 · see citing works